Clinical Pharmacokinetics and Pharmacodynamics of CSL112
AbstractCardiovascular diseases are the leading cause of death worldwide. Although there have been substantial advances over the last decades, recurrent adverse cardiovascular events after myocardial infarction are still frequent, particularly during the first year of the index event. For decades, high-density lipoprotein (HDL) has been among the therapeutic targets for long-term prevention after an ischemic event. However, early trials focusing on increasing HDL circulating levels showed no improvement in clinical outcomes. Recently, the paradigm has shifted to increasing the functionality of HDL rather than its circulati...
Source: Clinical Pharmacokinetics - March 16, 2023 Category: Drugs & Pharmacology Source Type: research
Correction to: Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment
(Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - March 13, 2023 Category: Drugs & Pharmacology Source Type: research
Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist
ConclusionCilofexor may be coadministered with inhibitors of P-gp, CYP3A4, or CYP2C8 without the need for dose modification. Cilofexor may be coadministered with OATP, BCRP, P-gp, and/or CYP3A4 substrates —including statins—without dose modification. However, coadministration of cilofexor with strong hepatic OATP inhibitors, or with strong or moderate inducers of OATP/CYP2C8, is not recommended. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - March 11, 2023 Category: Drugs & Pharmacology Source Type: research
